Association of polymorphisms in genes of factors involved in regulation of splicing of cystic fibrosis transmembrane conductance regulator mRNA with acute respiratory distress syndrome in children with pneumonia by Perez-Marques, Francesca et al.
RESEARCH Open Access
Association of polymorphisms in genes of
factors involved in regulation of splicing of
cystic fibrosis transmembrane conductance
regulator mRNA with acute respiratory
distress syndrome in children with
pneumonia
Francesca Perez-Marques1, Pippa Simpson2,3,4, Ke Yan2,3, Michael W. Quasney5, Nadine Halligan5,
Daniel Merchant1,3 and Mary K. Dahmer5*
Abstract
Background: Previous work has demonstrated a strong association between lung injury in African American
children with pneumonia and a polymorphic (TG)mTn region in cystic fibrosis transmembrane conductance (CFTR)
involved in the generation of a nonfunctional CFTR protein lacking exon 9. A number of splicing factors that
regulate the inclusion/exclusion of exon 9 have been identified. The objective of this study was to determine
whether genetic variants in these splicing factors were associated with acute respiratory distress syndrome (ARDS)
in children with pneumonia.
Methods: This is a prospective cohort genetic association study of lung injury in African American and non-
Hispanic Caucasian children with community-acquired pneumonia evaluated in the emergency department or
admitted to the hospital. Linkage-disequilibrium-tag single nucleotide polymorphisms (LD-tag SNPs) in genes of the
following splicing factors (followed by gene name) involved in exon 9 skipping PTB1 (PTBP1), SRp40 (SFRS1), SR2/
ASF (SFRS5), TDP-43 (TARDBP), TIA-1 (TIA1), and U2AF65 (U2AF2) were genotyped. SNPs in the gene of the splicing
factor CELF2 (CELF2) were selected by conservation score. Multivariable analysis was used to examine association
between genotypes and ARDS.
Results: The African American cohort (n = 474) had 29 children with ARDS and the non-Hispanic Caucasian cohort
(n = 304) had 32 children with ARDS. In the African American group multivariable analysis indicated that three
variants in CELF2, rs7068124 (p = 0.004), rs3814634 (p = 0.032) and rs10905928 (p = 0.044), and two in TIA1, rs2592178
(p = 0.005) and rs13402990 (p = 0.018) were independently associated with ARDS. In the non-Hispanic Caucasian
group, a single variant in CELF2, rs2277212 (p = 0.014), was associated with increased risk of developing ARDS.
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Conclusions: The data indicate that SNPs in CELF2 may be associated with the risk of developing ARDS in both
African American and non-Hispanic Caucasian children with pneumonia and suggest that the potential role of the
splicing factor CELF2 in ARDS should be explored further.
Keywords: ARDS, ALI, Acute lung injury, Pediatrics, Genetic association study, Pneumonia
Abbreviations: ARDS, Acute respiratory distress syndrome; CAP, Community acquired pneumonia; CELF2, CUGBP,
elav-like family member 2; CFTR, Cystic fibrosis transmembrane conductance regulator; FiO2, Inspired oxygen
fraction; IRB, Institutional Review Board; OI, Oxygenation index; LD-tag SNPs, Linkage-disequilibrium-tag single
nucleotide polymorphisms; LPS, Lipopolysaccharide; mRNA, messenger RNA; OSI, Oxygen saturation index;
PARDS, Pediatric acute respiratory distress syndrome; PaO2, Partial pressure of oxygen; PTB, Polypyrimidine tract-
binding protein; SNP, Single nucleotide polymorphism; TDP-43, HIV-1 TAR DNA binding protein; TIA-1, T-cell
intracellular antigen 1
Background
Community-acquired pneumonia (CAP) is an important
worldwide cause of pediatric morbidity and mortality.
The annual incidence of CAP in European and North
American children less than 5 years old is higher (34 to
40 cases per 1000) than the incidence seen at any other
time of life, with the exception of the elderly (>75–80
years) [1, 2]. In children in the USA, pneumonia ac-
counts for almost a third of all respiratory-related hospi-
talizations [3] with the burden of hospitalization highest
for children under 5 years of age [4]. In the developing
world the incidence of pneumonia in children under 5 is
reported to be 6 to 10 fold higher than that of developed
countries and mortality is also higher with a reported
rate of 1.3–2.6 % [5–10].
The response to pneumonia varies between individ-
uals. Some individuals with pneumonia have relatively
mild disease while others go on to develop acute respira-
tory distress syndrome (ARDS). The underlying patho-
physiological processes observed in ARDS include
disruption of the alveolar capillary barrier, alveolar edema,
inflammation and, in some cases, fibrosis [11, 12]. Studies
suggest that pediatric ARDS (PARDS) is similar to ARDS
in adults though the immaturity of the lung parenchyma
and immune systems in children suggest that there may
be significant differences in the development and outcome
of ARDS in children [13]. A number of variants in genes
for proteins involved in the pathophysiology of ARDS
have been reported to be associated with development of
ARDS or outcome from ARDS [14–16], though most of
the studies have been performed in adults. These observa-
tions suggest that genetic variability present in genes that
encode for proteins involved in ARDS pathophysiology
may play an important role in the variability observed in
the severity of CAP-induced lung injury.
Several studies in children have also identified the as-
sociation between genetic variants and lung injury or
PARDS [13]. Recently we demonstrated a strong associ-
ation in African American children with pneumonia
between lung injury and a polymorphic (TG)mTn site lo-
cated close to the splice junction between intron 8 and
exon 9 of the cystic fibrosis transmembrane conductance
regulator (CFTR) gene [17]. The (TG)mTn site is linked
to a defect in CFTR messenger RNA (mRNA) splicing
and reduced functional CFTR protein [18–24]. The ob-
served association with ARDS supports other findings
indicating that CFTR, a chloride channel found in epi-
thelial cells [25] and polymorphonuclear blood cells
[26–29], has a role in the development of ARDS. CFTR
is important in fluid clearance in the injured lung
[30, 31], is a negative regulator of the inflammatory
response [32–34], and the lack of functional CFTR on
neutrophils enhances development of ARDS triggered
by lipopolysaccharide (LPS) derived from gram nega-
tive bacteria in a mouse model [28]. Together these
results indicate that CFTR plays a role in ARDS in
children with pneumonia and predict that genetic variants
that affect the expression of functional CFTR, including
variants in proteins involved in the regulation of CFTR
mRNA splicing, will be associated with ARDS.
The (TG)mTn region in CFTR is composed of variable
numbers of TG and T repeats and affects the inclusion/
exclusion of exon 9. Alleles with 12 or more TGs and/or
5 or fewer Ts are associated with skipping of exon 9 and
synthesis of a non-functional CFTR protein missing part
of the nucleotide-binding domain-1 [18–24]. Regulation
of inclusion/exclusion of exon 9 during mRNA matur-
ation has been well-studied and a number of proteins in-
volved in splicing, and regulation of splicing, in that
region have been identified. Such proteins include
CUGBP, elav-like family member 2 (CELF2), HIV-1 TAR
DNA binding protein (TDP-43), polypyrimidine tract
binding protein (PTB), two SR proteins (SF2/ASF,
SRp40), T-cell intracellular antigen 1 (TIA-1), and
U2AF65 [35–38]. Based on our earlier study showing as-
sociation between specific alleles of (TG)mTn and acute
lung injury [17] we hypothesized that polymorphisms in
genes of the splicing factors involved in regulation of
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exon 9 skipping would be associated with ARDS in chil-
dren with pneumonia.
Methods
Study design
We performed a genetic association study to examine if
polymorphisms in splicing factors involved in exon 9
splicing of the CFTR gene are associated with ARDS in
pediatric patients enrolled in a prospective, multicenter
study of the role of genetic variation in lung injury in
children with community acquired pneumonia (CAP).
The outcome measure was a PaO2/FiO2 ratio ≤300, bi-
lateral infiltrates, and the absence of evidence of left
atrial hypertension which at the time the study was initi-
ated was defined as acute lung injury by the American
European Consensus Committee [39]. However, as the
more recent definitions of ARDS in both adults [40] and
children [41] have discontinued the use of the term
acute lung injury, and patients with a ratio of partial
pressure of oxygen (PaO2)/inspired oxygen fraction
(FiO2) ≤300 are currently considered to have ARDS, for
the purposes of this report we will refer to all patients
with a PaO2/FiO2 ratio ≤300 as having ARDS.
Study population
Children (2 weeks to 18 years old) of any race or eth-
nicity presenting to the Emergency Room, inpatient
unit or pediatric intensive care unit with a diagnosis
of CAP at either Le Bonheur Children’s Hospital,
Children’s Memorial Hospital, or Children’s Hospital of
Wisconsin were eligible for the study. The Institutional
Review Board (IRB) from each institution (University
of Tennessee Health Science Center IRB, Children’s
Memorial Hospital IRB, Children’s Hospital of Wisconsin
IRB) approved the study. Consent was obtained by indi-
viduals or their guardians for all participants except for
patients enrolled from the emergency department at
Children’s Hospital of Wisconsin where the IRB granted a
waiver of consent and for patients from the emer-
gency department at Le Bonheur Children’s where the
IRB waived consent if parents or guardians could not
be contacted.
Analysis was stratified by race, as the frequency of
genetic polymorphisms and the linkage disequilibrium
patterns differ between ethnicities and races [42, 43],
and such groups should be analyzed separately [44].
Only African Americans and non-Hispanic Caucasians
(52 % and 35 % of the cohort, respectively) were exam-
ined, as only these two groups had a sufficient number
of individuals for meaningful analysis. Race was self-
reported. This cohort was used previously to examine
the association between (TG)mTn alleles and acute lung
injury [17] and some members of this cohort have been
used in earlier studies [45, 46].
The inclusion criteria were children (2 weeks to 18
years old) with CAP defined as: 1) acute illness (<14 days
of symptoms); 2) new infiltrate on chest x-ray; 3) clinical
features compatible with pneumonia, including one of
the following: fever >37.8 °C, hypothermia <36 °C,
peripheral white blood count >10,000/μL or <4500/μL,
or >15 % immature neutrophils; and two of the follow-
ing: tachypnea (respiratory rate >2 standard deviations
from the mean for age), dyspnea, or hypoxemia (pulse
oximetry ≤94 % on room air on initial evaluation with-
out a known right to left cardiac shunt). Exclusion cri-
teria were diagnosis of immunodeficiency (primary or
acquired, including treatment with immunosuppressant
drugs), congenital heart disease, malignancy or history of
malignancy, need for oxygen home therapy, cystic fibro-
sis or residence at a chronic care facility within the pre-
vious 30 days or hospitalization within the previous
7 days. For the purposes of this study we have only ex-
amined African American and non-Hispanic Caucasian
children.
Selection of single nucleotide polymorphisms for
genotyping
The splicing factor genes selected were identified as po-
tential candidate genes related to ARDS after demon-
stration that the CFTR (TG)mTn polymorphic site
involved in regulation of exon 9 skipping was associated
with acute lung injury [17]. The splicing factors
(followed by their gene name) specifically involved in
regulating exon 9 skipping in the CFTR gene [35–38] in-
clude: CELF2 (CELF2), PTB (PTBP1), SRp40 (SFRS1),
SR2/ASF (SFRS5), TIA-1 (TIA1), TDP-43 (TARDBP),
and U2AF65 (U2AF2). Linkage disequilibrium-tag single
nucleotide polymorphisms (LD-tag SNPs) were identi-
fied in PTBP1, SFRS1, SFRS5, TARDBP, TIA1, and
U2AF2 using the program LD-select (available on the
Seattle SNPs website http://gvs.gs.washington.edu/GVS/)
which selects an optimal set of LD-tag SNPs based on
the r2 LD statistic [47]. The program was run with an
r2 threshold of 0.8 using the HAPMAP-CEU or –YRI
SNP genotyping database or the African American
SNP genotyping data from the Programs for Genomic
Applications database.
SNP selection included the region extending from
5 kb upstream of the transcription start site to 2 kb
downstream of the coding region to cover 5′ or 3′ re-
gions involved in regulating gene expression. The minor
allele frequency cutoff was 3 %. In African Americans 7
LD-tag SNPs in PTBP1, 5 in SFRS1, 5 in SFRS5, 11 in
TARDBP, 12 in TIA1, and 12 in U2AF2 were identified.
In Caucasians, 6 LD-tag SNPs in PTBP1, 3 in SFRS1, 4
in SFRS5, 5 in TARDBP, 3 in TIA1, and 10 in U2AF2
were identified. There were five LD-tag SNPs that could
not be genotyped successfully due to failure in the
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design, manufacturing, or genotyping assay including
rs9430171 in TARDBP, and rs504850 and rs2271757 in
U2AF2 in both African Americans and Caucasians,
rs8100561 (PTBP1) in African Americans only, and
rs188701 (U2AF2) in Caucasians only.
A different strategy was used for CELF2, as 331 and
162 LD-tag SNPs were identified in the cohorts of
African and European descent, respectively. Conse-
quently, SNPs genotyped in the CELF2 gene were se-
lected by conservation score using PhastCons [48] and
GERP [49]. A PhastCons score >0.7 and a GERP score >2
were used as selection criteria. A total of 20 or 15 SNPs
for the CELF2 gene were identified in individuals of
African and European descent, respectively. One of the
SNPs in the African American cohort failed the custom
design process (rs201112) and the Taqman assay for
rs790441 failed in both groups.
A priori power calculations using Quanto 1.2.3 [50, 51]
indicated that the African American and non-Hispanic
Caucasian cohorts were powered (using 80 % power) to
observe associations between SNPs and ARDS (using
population estimates for minor allele frequency from the
HAPMAP or Programs for Genomic Applications data-
base), giving minimal detectable odds ratios of approxi-
mately 2.1 to 4.3 depending upon the minor allele
frequency. SNPs with minor allele frequencies between
10 % and 49 % (77 % and 66 % of the selected SNPs in the
African American and non-Hispanic Caucasian groups,
respectively) had minimal detectable odds ratios of 2.1 to
2.7, while those for frequencies between 3 % and 10 %
ranged from 4.3 to 2.7.
Genotyping
DNA was extracted from whole blood using the Wizard
Genomic DNA Purification Kit (Promega, Madison, WI,
USA). Genotyping was performed blinded to the clinical
status of individuals. Genotyping of the LD-tag SNPs
was performed using 5′ exonuclease TaqMan assays
(Applied Biosystems, Foster City, CA, USA).
For all genotyping assays approximately 5–10 % of
randomly chosen samples were genotyped a second time
to verify reproducibility; average concordance was
99.9 % (104 assays had 100 % concordance and 3 others
had 96.4–97.8 % concordance). Call rates ranged from
99.4–100 %. Genotype frequencies of sites did not
deviate significantly from Hardy-Weinberg equilibrium
(significance set at p < 0.01) except for rs3765896
(TARDBP) in the African American cohort.
Statistical analysis
For the univariable analysis, either the two-sided chi-
square test or Fisher’s Exact test (when any cell in the
cross-tabulation had counts less than 5) was performed
to test for association between categorical variables and
the presence of ARDS. The Mann–Whitney U test was
used for the continuous variables (age, hospital length of
stay, room air pulse oximetry). Predictors that were
tested besides age included the various alleles in the spli-
cing genes (grouped as the presence of one or two
copies of specific alleles), the (TG)mTn site in CFTR
(grouped as 1 or 2 copies of high risk alleles), gender,
asthma, history of bronchopulmonary dysplasia, neuro-
logic disorder (defined as developmental delay and/or
history of seizures), and sickle cell anemia. As there was
a gap in age in this group, age was also categorized into
two groups for the analysis, <11 years and ≥11 years.
SNPs with a p value <0.2 were included in the multivari-
able analysis along with the covariates.
Multivariable logistical regression analysis was per-
formed using the development of ARDS as the dependent
variable. Initially variables, such as SNPs, were se-
lected for consideration in the model if the p value
was <0.2 in the univariate analysis. A stepwise selec-
tion approach, with 0.05 and 0.1 as significance levels
for entry into and staying in the model, was used for
selection of the variables in the final model. The ex-
ception was presence of asthma, which was always in-
cluded. SAS 9.2 (SAS Institute Inc., Cary, NC, USA)
was used for all the analyses.
Results
The demographic characteristics of the African American
and non-Hispanic Caucasian cohorts used for this
study have been described previously [17]. The African
American cohort is composed of 474 children (53 % male)
14 days to 18 years old with a median age of 2.1 years.
Comorbid conditions include asthma (20 %), sickle cell
disease (12 %), neurological disorders (8 %) defined as sei-
zures and/or developmental delay, and history of bronch-
opulmonary dysplasia (2 %). Of these patients 43 were
mechanically ventilated, 29 had ARDS and 3 died. The
non-Hispanic Caucasian group includes 304 children
(54 % male) 18 days to 17 years old with a median age of
4.0 years. Among these patients, 15 % have asthma, 8 %
have neurological disorders and 2 % have a history of
bronchopulmonary dysplasia, and 40 patients were mech-
anically ventilated, 32 had ARDS and 2 died.
Shown in Table 1 is a comparison of general char-
acteristics between children with and without ARDS
in these cohorts. The demographic characteristics and
co-morbidities do not differ significantly between chil-
dren with or without ARDS in either the African
American or non-Hispanic Caucasian children except
that in the non-Hispanic Caucasian cohort the ARDS
group is older (Table 1). As expected clinically related
measures of disease are significantly different between
those with and without ARDS. Of the African American
children with admission measurements of room air pulse
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oximetry (n = 20 patients with ARDS and 397 patients
without ARDS) saturation in room air was 87 % (range
50–98) and 95 % (range 48–100), respectively (p < 0.001);
for non-Hispanic Caucasian children with measurements
available (n = 23 patients with ARDS and 250 patients
without ARDS) saturation was 89 % (range 50–99) and
93 % (range 55–100), respectively (p = 0.001). Approxi-
mately 85 % of the patients with ARDS in each cohort had
a PaO2/FiO2 ≤ 200.
Polymorphic sites in genes for splicing proteins in-
volved in the regulation of inclusion or exclusion of
exon 9 in CFTR were genotyped. The SNPs selected for
genotyping were either LD-tag SNPs (PTBP1, SFRS1,
SFRS5, TIA1, TARDBP, U2AF2) or were highly conserved
sites (CELF2) as described in “Methods”. The minor al-
lele, and the minor allele frequency, of the SNPs geno-
typed in African American and non-Hispanic Caucasian
children with CAP are shown in Table S1 in Additional
file 1. The minor allele frequencies are similar to those
reported previously.
Multivariable logistic regression analysis was per-
formed to determine whether any of the genetic variants
in the splicing factors were associated with development
of ARDS after the genotype at the (TG)mTn site in CFTR
and other demographic or clinical factors that may
influence the severity of disease were considered. Var-
iables included in the analysis were age, gender, co-
morbid conditions, presence of one or more high risk
(TG)mTn allele, and any SNPs with a p value <0.2 in
the univariate analysis (Table 2). In African American
Table 1 Comparison of general characteristics of patients with
and without acute respiratory distress syndrome
Characteristics No ARDS ARDS pa
African Americans
Age (years), median (range) 2.1 (14 days
to 18.9)
5.9 (25 days
to 17.9)
0.19
Gender, n (%) male 230 (52) 19 (66) 0.15
Comorbidities, n (%)
Asthma 94 (21) 3 (10) 0.16
Bronchopulmonary dysplasiab 9 (2) 1 (3) 0.47
Neurological disordersc 31 (7) 5 (17) 0.06
Sickle cell disease 54 (12) 3 (10) >0.99
Mortality, n (%) 0 (0) 3 (10) <0.001
Admitted to hospital, n (%) 274 (62) 29 (100) <0.001
Admitted to PICU, n (%) 15 (3) 29 (100) <0.001
Mechanical ventilation, n (%) 14 (3) 29 (100) <0.001
Hospital length of stayd, median (range) 2 (0–19) 22 (6–101) <0.001
PaO2/FiO2, n (%)
≤ 100 na 16 (55) -
101 –≤ 200 na 8 (28) -
201 –≤ 300 na 5 (17) -
Non-Hispanic Caucasians
Age (years), median (range) 3.7 (18 days
to 17.8)
9.6 (63 days
to 17.9)
<0.001
Gender, n (%) male 151 (56) 14 (44) 0.21
Comorbidities, n (%)
Asthma 44 (16) 2 (6) 0.19
Bronchopulmonary dysplasiab 6 (2) 0 (0) >0.99
Neurological disordersc 19 (7) 5 (16) 0.15
Mortality, n (%) 0 (0) 2 (6) 0.01
Admitted to hospital, n (%) 209 (77) 32 (100) <0.001
Admitted to PICU, n (%) 17 (6) 32 (100) <0.001
Mechanical ventilation, n (%) 12 (4) 30 (94) <0.001
Hospital length of stayd, median (range) 3 (0–69) 17 (6–126) <0.001
PaO2/FiO2, n (%)
≤ 100 na 14 (44) -
101 –≤ 200 na 14 (44) -
201 –≤ 300 na 4 (12) -
ap value determined by Mann–Whitney test (age, hospital length of stay) or
chi-square test or Fisher’s Exact test (others); bhistory of bronchopulmonary
dysplasia (no subjects were on oxygen therapy at home); cneurological
disorders included seizures and/or developmental delay; dhospital length of
stay in days was calculated for survivors. n = 474 for African Americans and 304
for non-Hispanic Caucasians. ARDS acute respiratory distress syndrome, PICU
pediatric intensive care unit, PaO2/FiO2 partial pressure of oxygen/inspired oxygen
fraction, na not available
Table 2 Splicing factor variants included in the multivariable
analysis
African Americans Non-Hispanic Caucasians
GENE SNPs p SNPs p
PTBP1 rs351974 0.14
SFRS1 rs2233905 0.10
rs2233906 0.15
TARDBP rs3765896 0.11 rs3765896 0.13
rs1782455 0.12
TIA1 rs2289920 0.16 rs2592177 0.04
rs2166451 0.16
rs2592178 0.05
rs13402990 0.06
rs13024392 0.06
rs2921711 0.11
U2AF2 rs7247677 0.14 rs7247677 0.05
rs537728 0.09 rs617073 0.04
rs310445 0.12 rs10420401 0.11
CELF2 rs3814634 0.09 rs3814634 0.08
rs10905928 0.12 rs10905928 0.10
rs2209285 0.15 rs2277212 0.02
rs17149511 0.19
rs7068124 0.01
p value determined with the chi-square or Fisher’s exact test. SNP single
nucleotide polymorphism
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children, multivariable analysis indicated that three SNPs
in the CELF2 gene (rs7068124, rs3814634, rs10905928;
odds ratio (OR) = 4.28, 2.95, and 2.66, respectively) and
two SNPs in the TIA1 gene (rs25921789, rs13402990;
OR = 3.70 and 5.42, respectively) were significantly as-
sociated with development of ARDS (Table 3). The
high risk (TG)mTn alleles previously reported to be
associated with ARDS [17] remained independently
associated with ARDS (OR = 3.01) even in the pres-
ence of the indicated splicing variants. In Caucasians
a variant in CELF2, rs2277212 (OR = 3.22), was asso-
ciated with increased risk of development of ARDS.
As the SNPs examined in the CELF2 gene are not LD-
tag SNPs but rather were chosen by conservation scores
we examined whether the three SNPs in the African
American cohort associated with increased risk for
ARDS are in significant linkage disequilibrium. As
shown in Table 4, the three SNPs in CELF2 do not have
a high degree of linkage disequilibrium. The degree of
linkage disequilibrium between the two SNPS in TIA1
that were associated with ARDS was also very low.
Discussion
This study demonstrates that there is a significant as-
sociation between specific variants in CELF2, a gene
encoding for a splicing factor involved in controlling
the level of exon 9 skipping in CFTR, and risk of de-
veloping ARDS in children with pneumonia who do
not suffer from cystic fibrosis. Multivariable analysis
indicated that in African American children three variants
in CELF2, rs7068124, rs3814634 and rs10905928, were in-
dependently associated with ARDS. In addition, the previ-
ously reported association between high risk (TG)mTn
alleles and ARDS remained independently associated with
ARDS even when variants in genes encoding for splicing
factors were included in the analysis.
Our previous study showed association between high-
risk (TG)mTn alleles in the CFTR gene and ARDS in
African Americans but not in non-Hispanic Caucasians.
One possible explanation for this difference is that
intracellular levels of splicing factors differ between
Caucasians and African Americans resulting in a differ-
ence in the degree of exon 9 skipping and consequently
the level of functional CFTR with identical (TG)mTn al-
leles. As in vitro data indicate that modulating the
amount of TDP-43 affects the amount of exon 9 skip-
ping with a given (TG)mTn site [35], we hypothesized
that genetic variants that were associated with differ-
ences in levels of splicing factors might be associated
with ARDS even in the absence of association with high-
risk (TG)mTn alleles. A genetic variant in CELF2
(rs2277212) was associated with risk of ARDS in non-
Hispanic Caucasian children. Given that genetic struc-
ture and linkage-disequilibrium varies significantly be-
tween African Americans and non-Hispanic Caucasians,
it is not surprising that the CELF2 variant associated
with the risk of ARDS in non-Hispanic Caucasian chil-
dren is not one of the three identified in the African
American cohort.
The CELF2 SNPs associated with ARDS do not change
the amino acid sequence of CELF2, but appear to be in
transcriptional regulatory regions when evaluated using
HaploReg [52]. Epigenetic modifications on histones
demonstrate that rs2277212 is in an enhancer region in
B lymphocytes, primary monocytes and T cells. Interest-
ingly, this variant is in a binding motif for the transcrip-
tion factor STAT. The SNP at site rs7068124 is also in a
region with epigenetic marks on histones indicative of
an enhancer region in primary T helper cells, and in in-
dividuals of African descent it is in linkage disequilib-
rium with an SNP that alters a number of DNA binding
protein motifs. The variants rs10905928 and rs3814634
Table 3 Multivariable analysis of association between splicing
factors variants and acute respiratory distress syndrome
Variable Odds
ratio
95 % Confidence
interval
p
African Americans
CELF2: rs3814634 (GT/GG vs TT) 2.95 1.10–8.06 0.032
CELF2: rs7068124 (CT/TT vs CC) 4.28 1.58–11.64 0.004
CELF2: rs10905928 (AC/AA vs CC) 2.66 1.03–6.89 0.044
TIA1: rs2592178 (AG/AA vs GG) 3.70 1.49–9.15 0.005
TIA1: rs13402990 (AT vs AA) 5.42 1.34–21.9 0.018
High risk (TG)mTn alleles
a 3.01 1.27–7.14 0.012
Age group (≥11 years) 14.9 5.53–40.1 <0.0001
Asthma 0.55 0.15–2.00 0.36
Non-Hispanic Caucasians
CELF2: rs2277212 (TT vs AA/AT) 3.22 1.26–8.33 0.014
Age group (≥11 years) 9.20 3.93–21.6 <0.0001
Asthma 0.20 0.04–0.96 0.04
aChildren with one or more high risk (TG)mTn allele compared to children
with no high risk (TG)mTn alleles; n = 463 for African Americans, n = 304 for
Non-Hispanic Caucasians
Table 4 Linkage disequilibrium of variants associated with
acute respiratory distress syndrome in individuals of African
Descent
Gene SNP1 SNP2 r2a
CELF2 rs3814634 rs7068124 0.055
rs3814634 rs10905928 0.001
rs7068124 rs10905928 0.018
TIA1 rs2592178 rs13402990 0.004
ar2 statistic from HAPMAP data for Yoruban cohort
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are in regions that have been predicted to bind a number
of proteins that regulate transcription. In addition, the
ENCODE database indicates that rs10905928 is in a
region with a high level of monomethylated H4K20, an
epigenetic modification that has been implicated in a
number of processes including transcriptional regulation
and DNA replication [53, 54]. The location of these
variants in regulatory regions suggest that they may be
involved in regulating CELF2 protein levels; however, fu-
ture studies will be required to determine whether these
variants are associated with regulation of CELF2 levels
and whether they are indeed the causative sites.
The three sites in CELF2 associated with ARDS in
African Americans are not in significant LD suggesting
that there may be multiple sites in the CELF2 gene that
have a functional impact on CELF2 in this population.
Consequently, in future studies each of these three
CELF2 SNPs, and all of the SNPs with which they are in
significant LD, will need to be examined for possible ef-
fects on expression of CELF2 and binding of their puta-
tive binding protein regulatory proteins. Such studies
will also be required for the CELF2 SNP associated with
ARDS in the Caucasian population.
In African American children, two variants in TIA1,
rs2592178 and rs13402990, were also associated with
risk of developing ARDS. Epigenetic modifications in the
region surrounding rs2592178 suggest it is located in a
promoter and/or enhancer region in a number of cell
types including primary monocytes, T cells and neutro-
phils. The potential role of the variant rs2592178 on ex-
pression of TIA1 is also indicated by data identifying it
as an expression quantitative trait locus [52]. rs13402990
is not in a regulatory region itself but it is in complete
LD with five other SNPs in individuals of African des-
cent that are in the promoter and/or an enhancer region
in many cell types including monocytes, T cells, and
neutrophils, and some of these SNPs alter regulatory
binding protein motifs. There was no association be-
tween genetic variants in TIA1 and ARDS in non-His-
panic Caucasians. Interestingly, the two polymorphic sites
associated with ARDS in African Americans are not
polymorphic in non-Hispanic Caucasians. It is unclear
whether the lack of replication between these two groups
is due to a significant difference between African Ameri-
cans and Caucasians or whether the association observed
in the African Americans is a false positive. Future studies
will have to resolve this question.
This is the first report that variations in genes that
regulate mRNA splicing are associated with develop-
ment of ARDS. The specific variants associated with
ARDS in CELF2 and TIA1 have not been reported to be
associated with other diseases. However, there are re-
ports that other very rare variants in CELF2 [55–57] and
TIA1 [58] are associated with other disease states. The
variants associated with ARDS in this study do not result
in a change in the amino acid sequence of the protein.
However, these variants appear to be in regulatory re-
gions of their respective gene, consequently, they may be
associated with differences in levels of their protein
product. The CELF2 gene is also in a region in which
structural genetic variants have been reported (http://
www.ncbi.nlm.nih.gov/dbvar/?term=celf2), so it is pos-
sible that the SNPs associated with ARDS are in linkage
disequilibrium with regions of the gene with deletions or
insertions.
Because the genes examined in this study were chosen
based on their biological role in the regulation of exon 9
skipping in CFTR, it is tempting to assume that the as-
sociation between these SNPs and ARDS is due to their
effect on splicing factors affecting the splicing of CFTR.
However, the proteins encoded by CELF2 and TIA1 are
involved in regulating the splicing of many different
genes and can also affect translation, mRNA stability,
and in the case of TIA-1, transcription [59–61]. Interest-
ingly, CELF2 expression is increased during T-cell sig-
naling, resulting in widespread changes in splicing and
in the T-cell transcriptome [62]. Future studies will be
needed to determine whether the increased risk of devel-
opment of ARDS observed with these variants is also
seen in other cohorts and whether association between
these variants and risk of ARDS is due solely, or even in
part, to their impact on the amount of functional CFTR.
The association between a variant in CELF2 and de-
creased risk of ARDS without any association between
the high risk (TG)mTn alleles and ARDS in non-
Hispanic Caucasians suggests that CELF2 may impact
the risk of developing ARDS by other means in
addition to the effect of exon 9 inclusion/exclusion in
CFTR.
The observation that two splicing genes involved in
exon 9 skipping in CFTR contain variants that appear to
impact upon the risk of ARDS in African American chil-
dren suggests that the previously observed association
between (TG)mTn and ARDS in African American chil-
dren with CAP may be meaningful. In addition, the find-
ing that genetic variants in CELF2, TIA1 and the
(TG)mTn site in CFTR are all independently associated
with ARDS suggests that children with multiple variants
are likely to be at greater risk of developing CAP-
induced ARDS than children with fewer variants. A lar-
ger cohort of African American children with ARDS will
be required to examine this question.
There are several limitations to this study. The rela-
tively small size of the cohort resulted in the study being
powered to identify associations with minimum odds ra-
tios of 2.1–2.7 for SNPs with minor allele frequencies
between 0.49 and 0.1, and 2.7–4.2 for minor allele fre-
quencies between 0.09 and 0.03. Consequently, there
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was limited power for SNPs with minor allele frequen-
cies below 0.10 and variants with smaller effects may not
have shown a statistically significant association with
ARDS. Another limitation is that there are not yet any
data demonstrating that the variants associated with
ARDS have a functional impact on the level or function
of the corresponding protein. However, the CELF2 vari-
ants are at highly conserved sites and in regions that
appear to be involved in transcriptional regulation, sug-
gesting that they may be associated with the level of
CELF2. The children that were identified as having
ARDS in this study had a PaO2/FiO2 ratio ≤300 and bi-
lateral chest infiltrates, which at the time of study design
and enrollment were components of the definition of
acute lung injury published by the American European
Consensus Committee [39]. However, the newly recom-
mended definitions of ARDS in both adults [40] and
children [41] expanded the respiratory criterion for
ARDS to include patients who previously met the criter-
ion for either acute lung injury or ARDS and have rec-
ommended discontinuing the use of the term acute lung
injury. Although the new definition of pediatric ARDS
recommends using the oxygenation index (OI) or oxy-
gen saturation index (OSI) as the respiratory criterion
for ARDS, a PaO2/FiO2 ratio ≤300 was used in our co-
horts because OI or OSI could not be calculated for all
the patients in our cohort. Last, most of the patients
with ARDS in this study had moderate to severe ARDS,
so the findings might not be generalizable to patients
with mild ARDS.
Conclusions
In summary, multivariable analysis adjusted for the
(TG)mTn site in CFTR and for demographic and clinical
factors, has identified an association between polymor-
phisms in CELF2 and risk of developing ARDS in both
African American and non-Hispanic Caucasian children
with pneumonia. This is the first study to report associ-
ation between variants in proteins involved with regula-
tion of mRNA splicing and stability with ARDS. This
finding supports the previously observed association be-
tween high risk (TG)mTn alleles in CFTR and lung injury
in African American children with pneumonia and sug-
gests that CFTR and splicing factors that affect levels of
functional CFTR may be involved in the degree of lung
injury observed in African American and potentially in
non-Hispanic Caucasian children with pneumonia. How-
ever, future studies will be required to determine whether
this association can be replicated in additional, larger
cohorts, whether these SNPs are associated with altered
levels of protein product, and whether their effect is
mediated by an effect on CFTR mRNA splicing. Such
studies will begin to answer the question of whether
these genetic variants should be considered in studies
examining whether biomarkers are able to help predict
those at greatest risk of developing ARDS and whether
agents that modify CFTR function might be therapeutic-
ally useful in a subset of patients at risk of developing
ARDS.
Key messages
 Genetic variants in CELF2, a gene encoding a
protein involved in regulation of splicing of CFTR
mRNA, are associated with ARDS in both African
American and non-Hispanic Caucasian children
with pneumonia
 CELF2 variants associated with ARDS are in regions
involved in transcriptional regulation
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